Price movement over the last 24 hours
Alcon AG vs Atlassian Corporation PLC — how do they compare? Alcon AG trades at $66.86 (market cap $32.69B), while Atlassian Corporation PLC trades at $85.5 (market cap $22.43B). The key difference: Alcon AG is the larger of the two by market cap, and Alcon AG pays a 0.54% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals.
| ALC | TEAM | |
|---|---|---|
Market Cap | $32.69B | $22.43B |
Sector | Health | Technology |
52-Week High | $92.22 | $220.89 |
52-Week Low | $62.02 | $57.15 |
Enterprise Value | $36.28B | $22.54B |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Atlassian (TEAM) trades at $88.39, up 5.43% with bullish technical signals despite negative profitability metrics. The stock shows strong revenue growth from $2.8B in 2022 to $5.2B in 2025, though net losses persist. Recent earnings beats and cloud revenue momentum of 29% in Q3 FY26 support optimism. Analyst consensus is strongly bullish with 30 buy ratings and a $120.29 price target, representing 36% upside potential.
The outlook remains positive driven by enterprise adoption and AI integration, but investors face risks from persistent losses, high valuation multiples, and competitive pressures. With improving margins and strong institutional support, TEAM offers growth exposure but requires tolerance for current unprofitability and market volatility.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →